This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Grindex | |
Industry | Pharmaceuticals |
Founded | 1946 |
Headquarters | 53 Krustpils St, Riga , Latvia |
Key people | Kirovs Lipmans(Chairman of the Council), Juris Hmelnickis (CEO), Janis Romanovskis (Chief Finance and Administrative Officer), Andrejs Liberts, (Commercial director) |
Products | Mildronate; Ftorafur |
Production output | Pharmaceuticals |
Revenue | 187 million EUR (2020) |
29,142,630 (2022) | |
Total assets | 198,324,446 Euro (2022) |
Owner | Liplat Holding, Ltd. |
Number of employees | 1498 (2021) |
Subsidiaries | JSC Kalceks, JSC Tallinn Pharmaceutical Plant, HBM Pharma Ltd. |
Website | www.grindeks.eu |
JSC Grindex (branded as Grindex), or simply Grindeks, is an internationally operating Latvian pharmaceutical company with headquarters in Riga, Latvia. Its portfolio consists of original products, generics, and active pharmaceutical ingredients. It mostly focuses on cardiovascular, central nervous system, anti-cancer, and diabetes medicines. Grindex is the leading pharmaceutical manufacturer in the Baltic States. In 2021, Grindex exported products to more than 90 countries.
Grindex Group consists of JSC Grindex and its four subsidiaries — JSC Kalceks (Latvia), HBM Pharma Ltd. (Slovakia), JSC Tallinn Pharmaceutical Plant (Estonia) and Namu apsaimniekošanas projekti Ltd. (Latvia).